Amylyx Pharmaceuticals, Inc. Cash Flow Statement

Cash Flow Statement Dec2021 Dec2022 Dec2023 Dec2024
Operating Activities
Net Income -87.93M-199.48M49.05M-301.37M
Depreciation and Depletion 0.05M0.49M1.09M0.90M
Share-based Compensation 3.14M21.71M37.16M33.04M
Gains from Sales and Divestitures 0.19M0.71M
Gains from Investment Securities 5.34M8.48M9.82M7.73M
Asset Writedowns and Impairment 0.96M
Non-cash Items 15.63M2.06M3.88M3.67M
Cash from Operations -74.80M-179.87M11.92M-167.65M
Depreciation, Depletion & Amortization
Amortizatization of Intangibles -0.12M2.06M9.94M9.86M
Depreciation & Amortization (CF) 0.05M0.49M1.10M0.90M
Change in Working Capital
Change in Receivables 15.31M24.74M-39.60M
Change in Inventory 9.77M73.13M9.25M
Change in Account Payables 0.67M1.85M15.88M-19.10M
Change in Accured Expenses 21.60M-59.81M
Other Working Capital Changes 4.49M5.22M3.23M-4.99M
Investing Activities
Capital Expenditures 0.35M2.53M1.24M0.16M
Change in Intangibles 36.20M
Change in Acquisitions & Divestments 3.00M179.41M394.12M344.00M
Cash from Investing Activities -46.41M-238.99M92.05M75.65M
Financing Activities
Other financing activities 2.47M
Cash from Financing Activities 158.51M431.79M3.54M0.35M
Additional items
Exchange Rate Effect 0.01M-0.07M0.16M-0.44M
Change in Cash 37.31M12.87M107.67M-92.08M
Free Cash Flow -75.15M-182.40M10.68M-167.80M
Net Cash Flow 37.30M12.93M107.52M-91.64M